Page last updated: 2024-09-04

pomalidomide and epz-6438

pomalidomide has been researched along with epz-6438 in 1 studies

Compound Research Comparison

Studies
(pomalidomide)
Trials
(pomalidomide)
Recent Studies (post-2010)
(pomalidomide)
Studies
(epz-6438)
Trials
(epz-6438)
Recent Studies (post-2010) (epz-6438)
6231215521138110

Protein Interaction Comparison

ProteinTaxonomypomalidomide (IC50)epz-6438 (IC50)
[Histone H3]-lysineRattus norvegicus (Norway rat)0.004
Polycomb protein EEDHomo sapiens (human)0.0153
Histone-binding protein RBBP4Homo sapiens (human)0.004
Polycomb protein SUZ12Homo sapiens (human)0.004
Histone-lysine N-methyltransferase EZH2Homo sapiens (human)0.0364
Zinc finger protein AEBP2Homo sapiens (human)0.004
Histone-lysine N-methyltransferase EZH1Homo sapiens (human)0.004

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A1

Other Studies

1 other study(ies) available for pomalidomide and epz-6438

ArticleYear
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Molecular oncology, 2018, Volume: 12, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases

2018